At a glance
ClinicalIndex Comparison RecordPhase 2Recruiting· 100 target
Drug / intervention
OC-IgT cellsbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Innovative Treatment of Ovarian Cancer Based on Immunogene-modified T Cells (IgT)
In Brief
A Phase 2 clinical trial evaluating OC-IgT cells for Ovarian Cancer. Currently recruiting, targeting 100 participants across 1 site.
Detailed Summary
The primary objectives are to evaluate the safety and efficacy of infusion of autologous ovarian cancer immunogene-modified T cells (OC-IgT cells).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Cancer
CountriesChina
Collaborators--
Timeline
Phase 2Recruiting
2018201920202021202220232024202520262027202820292030
First PostedJun 2017
Enrollment StartMay 2025
TodayJul 2026
Primary CompletionSep 2028
Study CompletionDec 2029
First PostedJun 14, 2017
Enrollment StartMay 1, 2025
Primary CompletionSep 30, 2028
Study CompletionDec 31, 2029
TodayJul 1, 2026
Enrollment to primary: 3.4 yearsPosted 9.0 years agoPrimary completion in 2.2 years
Interventions
OC-IgT cellsbiological
Autologous human OC-IgT cells.